A retrospective cohort of 228 patients from the Memorial Sloane Kettering Cancer Center (MSKCC) and University of Pennsylvania who were treated with second-generation CD19 CAR-T cells was established; 137 of these patients were non-Hodgkin lymphoma (NHL) patients, 91 of whom were acute lymphocytic leukemia (ALL) patients. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.